当前的COVID-19大流行对医疗系统，包括HSCT，造成了前所未有的压力。多个国际组织已经制定了管理大流行背景下HSCT不同方面的指南。在比较2019年和2020年的情况下，我们的移植中心进行了相同数量的移植手术。在两个时期，移植手术主要是为患有急性白血病的患者进行的；因此，在大流行的限制下，紧急标准得到了尊重。同胞供体和脐带血单位的移植数量保持不变，而无关供体的移植数量增加，尤其是来自欧洲的库存，而同倍异体供体的移植则减少了。这样做是考虑到所有分离制品都必须经过冷冻保存的必要性。我们决定不冷冻保存骨髓制品，因为在此过程中CD34+细胞计数会大幅减少的风险更大。对于只有同半相合供体的紧急情况，我们选择使用G-CSF刺激后的PBSC。在HSCT后，进行了PTCY GvHD预防措施，+3 +5天，环孢素A，从第100天缓慢减退，直到HSCT后第90天的麦考菲酸。实施的变化并不会影响移植后的结果，如移植物失败、败血症和GVHD。由于后勤困难，我们从2020年3月的锁定期开始直到2020年9月停止了我们的CAR-T计划。根据国际指南，我们能够继续我们的HSCT计划，以确保患有血液病的病人获得生命挽救的治疗，这个过程是不能推迟的。版权所有©2023 Elsevier Ltd.

The current COVID-19 pandemic has placed unprecedented stress on the healthcare system, including HSCT. Several international organizations have created guidelines for managing different aspects of HSCT in the context of the pandemic. Comparing 2019 and 2020, our transplant center performed the same number of transplants. In both periods, transplants were mainly for patients with acute leukemia; thus, the urgency criteria was respected in light of pandemic restraints. Transplants by sibling donors and cord blood units remained the same, while transplants by unrelated donors were increased, in particular from European registries, and transplants by haploidentical donors were decreased. This change was made in light of the necessity of cryopreserving all apheresis products. We decided against cryopreserving bone marrow products due to the greater risk of drastic reduction in CD34 + cell count during the process. For urgent cases with only a haploidentical donor available, we opted for the use of PBSC following stimulation with G-CSF. GvHD prophylaxis was performed with PTCY on days + 3 + 5, cyclosporine with tapering from day + 100, and mycophenolic acid until day + 90 post-HSCT. Post-transplant outcomes such as graft failure, sepsis, and GVHD were not affected by the changes implemented. As a result of logistic difficulties, we halted our Car-T program from the start of the lockdown in March 2020 until September 2020. In accord with international guidelines, we were able to continue our HSCT program in the order to ensure a lifesaving treatment for patients with hematologic diseases for whom this procedure cannot be postponed.Copyright © 2023. Published by Elsevier Ltd.